Asterias Biotherapeutics Inc. (AST) Stock Rating Reaffirmed by HC Wainwright


Asterias Biotherapeutics Inc. (NYSEMKT:AST)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Sunday. They presently have a $10.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 157.73% from the stock’s previous close.
Several other equities analysts have also recently commented on AST. FBR & Co reissued a “buy” rating on shares of Asterias Biotherapeutics in a research note on Thursday, May 26th. Rodman & Renshaw reissued a “buy” rating and set a $10.00 target price on shares of Asterias Biotherapeutics in a research note on Tuesday, May 17th. Zacks Investment Research cut shares of Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 31st. Finally, Chardan Capital began coverage on shares of Asterias Biotherapeutics in a research note on Monday, May 23rd. They set a “buy” rating and a $5.50 target price on the stock. Five analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $7.75.
Asterias Biotherapeutics (NYSEMKT:AST) opened at 3.88 on Friday. Asterias Biotherapeutics has a 52 week low of $2.30 and a 52 week high of $6.40. The stock’s market cap is $176.22 million. The company’s 50 day moving average is $2.93 and its 200 day moving average is $3.59.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Asterias Biotherapeutics (NYSEMKT:AST) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.07. The firm earned $1.53 million during the quarter, compared to analyst estimates of $1.14 million. Equities analysts predict that Asterias Biotherapeutics will post ($0.73) earnings per share for the current year.
A hedge fund recently raised its stake in Asterias Biotherapeutics stock. State Street Corp boosted its stake in Asterias Biotherapeutics Inc. (NYSEMKT:AST) by 5.5% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 96,218 shares of the company’s stock after buying an additional 5,000 shares during the period. State Street Corp owned 0.26% of Asterias Biotherapeutics worth $452,000 at the end of the most recent reporting period.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer, and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia.

Receive News & Ratings for Asterias Biotherapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Asterias Biotherapeutics Inc. and related companies with’s FREE daily email newsletter.

Be the first to comment on "Asterias Biotherapeutics Inc. (AST) Stock Rating Reaffirmed by HC Wainwright"

Leave a comment

Your email address will not be published.